Curriculum Vitae

Date Prepared: 12/17/2022

Name: Andy Junghyun Kim Address: 209 Washington St.

Apt 4

Brookline, MA 02445

Mobile Phone 617-899-5380

Email andyjhki@gmail.com

Education

8/2014-12/2017 Bachelor of Science, Physics Emory University

Professional Positions

8/2016-12/2017	Teaching Assistant, Physics	Emory University
1/2017-12/2017	Research Assistant, Experimental Biophysics	Emory University

6/2018-6/2019 Category Specialist, Electronics and Walmart U.S. eCommerce

Entertainment

9/2019- Clinical Research Assistant, Infectious Diseases Brigham and Women's Hospital

Awards, Honors, and Prizes

11 W W W W 11 W 11 W W			
2014	Ontario Scholar	Iroquois Ridge High School	
2014	Halton District School Board Proficiency Award	Iroquois Ridge High School	
2014	Senior Book Award, Physics	Iroquois Ridge High School	
2015	Dean's List	Emory University	
2015	Emory College Grant	Emory University	
2015	W.C. McWhorter Family Grant	Emory University	
2017	Sigma Pi Sigma	Emory University	
2022	Honorable Mention, Research Staff Excellence	Brigham and Women's Hospital	

Award

Community Service and Outreach

8/2015-12/2017 Volunteer Emory Clinic

5/2016-8/2017 Volunteer Newton-Wellesley Urgent Care Center 2/2021- Volunteer Brookline Senior Center Chess Club

3/2022- Member, Board of Directors Boylston Chess Foundation

Scholarship

Peer reviewed publications in print or other media

- 1. Weber BN, Zhou G, **Kim A**, Pearson JC, Stone J, DiCarli M, Nikiforow S, Woolley A. Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study. *Open Forum Infect Dis.* 2021;8(2). doi:10.1093/ofid/ofab012
- 2. Moll M, Zon RL, Sylvester KW, Rimsans J, Chen EC, Ghosh AJ, Abston E, **Kim A**, Rutherford H, Mitre X, Hakim A, Connell NT, Battinelli E, Fredenburgh LE, Baron RM, Hobbs BD, Cho MH, Mittleman MA, Woolley AE, Connors JM. Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis. *Thromb Res.* 2021;203:57-60. doi:10.1016/j.thromres.2021.04.009

- 3. North CM, Barczak A, Goldstein RH, Healy BC, Finkelstein DM, Ding DD, **Kim A**, Boucau J, Shaw B, Gilbert RF, Vyas T, Reynolds Z, Siddle KJ, MacInnis BL, Regan J, Flynn JP, Choudhary MC, Vyas JM, Laskowski K, Dighe AS, Lemieux JE, Li JZ, Baden LR, Siedner MJ, Woolley AE, Sacks CA. Determining the Incidence of Asymptomatic SARS-CoV-2 among Early Recipients of COVID-19 Vaccines: A Prospective Cohort Study of Healthcare Workers before, during and after Vaccination [DISCOVER-COVID-19]. *Clin Infect Dis.* 2021;ciab643. doi:10.1093/CID/CIAB643
- 4. Weber BN, Siddiqi H, Zhou G, Vieira J, Kim A, Rutherford H, Mitre X, Feeley M, Oganezova K, Varshney AS, Bhatt AS, Nauffal V, Atri DS, Blankstein R, Karlson EW, Di Carli M, Baden LR, Bhatt DL, Woolley AE. Relationship Between Myocardial Injury During Index Hospitalization for SARS-CoV-2 Infection and Longer-Term Outcomes. *J Am Heart Assoc*. 2021;10:e022010. doi: 10.1161/JAHA.121.022010
- 5. Yen TE, **Kim A**, Benson ME, Ratnaparkhi S, Woolley AE, Mc Causland FR. Serum Sodium, Patient Symptoms, and Clinical Outcomes in Hospitalized Patients with COVID-19. *J Prim Care Community Health*. 2022; 13:21501319211067349. doi: 10.1177/21501319211067349
- 6. Naz-McLean S, Kim A, Zimmer A, Laibinis H, Lapan J, Tyman P, Hung J, Kelly C, Nagireddy H, Narayanan-Pandit S, McCarthy M, Ratnaparkhi S, Rutherford H, Patel R, Dryden-Peterson S, Hung DT, Woolley AE, Cosimi LA. Feasibility and lessons learned on remote trial implementation from TestBoston, a fully remote, longitudinal, large-scale COVID-19 surveillance study. *PLoS One*. Published on June 3, 2022. doi: 10.1371/journal.pone.0269127
- 7. Woolley AE, Dryden-Peterson S, **Kim A**, Naz-McLean S, Kelly C, Laibinis HH, Bagnall J, Livny J, Ma P, Orzechowski M, Shoresh N, Gabriel S, Hung DT, Cosimi LA. At-home Testing and Risk Factors for Acquisition of SARS-CoV-2 Infection in a Major US Metropolitan Area. *Open Forum Infect Dis*. 2022;9(11). doi: 10.1093/ofid/ofac505
- 8. Weber B, Parks S, Huck DM, **Kim A**, Bay C, Brown JM, Divakaran S, Hainer J, Bibbo C, Taqueti V, Dorbala S, Blankstein R, Woolley AE, Di Carli MF. Prior SARS-CoV-2 Infection is associated with Coronary Vasomotor Dysfunction as assessed by Coronary Flow Reserve from Cardiac Positron Emission Tomography. *J Am Heart Assoc*. 2022;11:e025844. doi: 10.1161/JAHA.122.025844
- 9. Dryden-Peterson S, **Kim A**, Joyce M, Johnson JA, Kim AY, Baden LR, Woolley AE. Bebtelovimab for high-risk outpatients with early COVID-19 in a large US health system. *Open Forum Infect Dis*. 2022;9(12). doi: 10.1093/ofid/ofac565
- 10. Dryden-Peterson S, **Kim A**, Kim AY, Caniglia EC, Lennes I, Patel R, Gainer L, Dutton L, Donahue E, Gandhi RT, Baden LR, Woolley AE. Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system. *Ann Intern Med.* doi: 10.7326/M22-2141

Research publications without named authorship

Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bansaci AM, Woolley AE, Nikiforow S, Lin N, Sagar M, Schrager H, Huckins DS, Axelrod M, Pincus MD, Fleisher J, Sacks CA, Dougan M, North CM, Halvorsen YD, Thurber TK, Dagher Z, Scherer A, Wallwork RS, Kim AY, Schoenfeld S, Sen P, Neilan TG, Perugino CA, Unizony SH, Collier DS, Matza MA, Tinh JM, Bowman KA, Meyerowitz E, Zafar A, Drobni ZD, Bolster MB, Kohler M, D'Silva KM, Dau J, Lockwood MM, Cubbison C, Weber BN, Mansour MK; BACC Bay Tocilizumab Trial Investigators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020; 383:2333-2344. doi: 10.1056/NEJMoa2028836

- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett J, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021; 384:403-16. doi: 10.1056/NEJMoa2035389
- 3. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schodel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021; 385:1774-85. doi: 10.1056/NEJMoa2113017
- 4. El Sahly HM, Baden LR, Essink B, Montefiori D, McDermont A, Rupp R, Lewis M, Swaminathan S, Griffin C, Fragoso V, Miller VE, Girard B, Paila YD, Deng W, Tomassini JE, Paris R, Schodel F, Das R, August A, Leav B, Miller JM, Zhou H, Pajon R; Coronavirus Efficacy (COVE) Study Group. Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. *J Infect Dis.* Published on May 10, 2022. doi: 10.1093/infdis/jiac188
- 5. Lin D, Baden LR, Sahly HM, Essink B, Neuzil KM, Corey L, Miller J; **COVE Study Group**. Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial. *JAMA Netw Open*. 2022; 5(6):e2215984. doi: 10.1001/jamanetworkopen.2022.15984

Non-peer reviewed publications in print or other media

1. Eraslan B, Brown E, Benson M, Amir-Zilberstein L, Park S, Tusi B, Pokatayev V, Hecht C, Pischesha N, **Kim A**, Zhang S, Gaca A, Chantous F, Delorey T, Livny J, Baden L, Rozanblatt-Rosen O, Graham D, Regev A, Seaman M, Woolley A, Cosimi L, Hung D, Derguine J, Xavier R. Functional analyses and single cell immunoprofiling uncover sex-specific differences in SARS-CoV2 immune memory development. *Res Sq.* Published on March 15, 2022. doi: 10.21203/RS.3.RS-1416969/V1

Abstracts, poster presentations, and exhibits presented at professional meetings

- 1. Woolley AE, Goldberg HJ, Singh SK, Givertz MM, Mehra MR, Coppolino A, Cheng V, **Kim J**, Fanikos J, Harrington DP, Mallidi HR, Baden LR. DONATE HCV Trial 2 Year Update. IDWeek, October 2019. Oral Presentation.
- 2. Kanjilal S, Baker M, Woolley AE, Rhee C, Petrides AK, **Kim J**, Patel R, Zaffini R, Klompas M, Brigl M . 427. Variation in SARS-CoV-2 molecular diagnostic test performance in symptomatic versus asymptomatic populations. *Open Forum Infect Dis*. 2020;7(Supplement_1):S280-S280. doi:10.1093/ofid/ofaa439.621
- 3. Woolley AE, Goldberg HJ, Singh SK, Mehra MR, Givertz MM, Coppolino A, Sharma NS, Keshk MA, Rinewalt DE, **Kim A**, Rutherford H, Fankos J, Harrington D, Mallidi HR, Baden LR. Long-Term Outcomes in Heart and Lung Transplants from HCV-Viremic Donors to Uninfected Recipients: The Donate HCV Trial. *J Hear Lung Transplant*. 2021;40(4):S73. doi:10.1016/j.healun.2021.01.1919
- 4. Weber B, Siddiqi H, Vieira J, Zhou G, **Kim A**, Rutherford H, Mitre X, Feeley M, Oganezova K, Varshney A, Bhatt A, Nauffal V, Atri D, Blankstein R, DeCarli M, Baden L, Bhatt D, Woolley A. RELATIONSHIPS BETWEEN MYOCARDIAL INJURY, INDEX HOSPITALIZATION

- CHARACTERISTICS, AND LONGER-TERM OUTCOMES IN SARS-COV-2 INFECTION. *J Am Coll Cardiol*. 2021;77(18):3025. doi:10.1016/S0735-1097(21)04380-1
- 5. Siddiqi H, Vieira J, Zhou G, Weber B, **Kim A**, Rutherford H, Varshney A, Bhatt A, Woolley A, Nohria A. CARDIOVASCULAR COMPLICATIONS IN HOSPITALIZED PATIENTS WITH SARS-COV-2 INFECTION AND HISTORY OF CANCER. *J Am Coll Cardiol*. 2021;77(18):3097. doi:10.1016/S0735-1097(21)04452-1
- 6. Siddiqi H, Vieira J, Weber B, **Kim A**, Rutherford H, Varshney A, Bhatt A, Mehra M, Woolley A, Stewart G. STATIN USE AND OUTCOMES IN HOSPITALIZED PATIENTS WITH SARS-COV-2 INFECTION. *J Am Coll Cardiol*. 2021;77(18):3091. doi:10.1016/S0735-1097(21)04446-6
- 7. Powell M, Sherman AC, Klopfer J, Desjardins M, Cheng C, Gilboa T, Senussi Y, Ratnaparkhi S, Mitre X, Feeley M, Avila Paz A, **Kim AJ**, Rutherford H, Cauley J, Kim A, Park J, Liakos A, Woolley A, Walt D, Baden L. Longitudinal Assessment of Humoral Responses to COVID-19 Vaccines in Solid Organ Transplant Recipients. *Open Forum Infect Dis.* 2021;8(Supplement_2):S16-S17. doi:10.1093/ofid/ofab466.024
- 8. Weber B, Parks S, **Kim A**, Bay C, Brown J, Divakaran S, Hainer J, Bibbo C, Taqueti VR, Dorbala S, Blankstein R, Woolley A, DiCarli M. PRIOR SARS-COV-2 INFECTION IS ASSOCIATED CORONARY VASOMOTOR DYSFUNCTION AS ASSESSED BY CORONARY FLOW RESERVE FROM CARDIAC POSITRON EMISSION TOMOGRAPHY. *J Nucl Cardiol*. 2021;28(5):2451. doi:10.1007/s12350-021-02760-1
- 9. Yen TE, **Kim A**, Rutherford H, Ratnaparkhi S, Woolley AE, McCausland FR. Serum Sodium and Patient Symptoms in COVID-19 Hospitalizations. *J Am Soc Nephrol*. 2021;32(Supplement):106.
- 10. Harris CE, Coakley L, Zhou G, Frankel K, Matiello E, Melanson F, Montoya K, Hickey M, **Kim A**, Rinewalt D, Givertz MM, Stewart G, Mallidi HR, Mehra MR, Baden LR, Woolley AE. The Impact of Left Ventricular Assist Device Infections on Clinical Outcomes. *J Hear Lung Transplant*. 2022;41(4):S283. doi:10.1016/j.healun.2021.01.695
- 11. Jering K, **Kim A**, Frankel K, Coakley L, Weber B, Harris C, Ellis EJ, Givertz MM, Mallidi HR, Baden LR, Mehra MR, Woolley AE. Antibody Responses to COVID-19 Vaccination in Patients with Left Ventricular Assist Devices. *J Hear Lung Transplant*. 2022;41(4):S77. doi:10.1016/j.healun.2022.01.177
- 12. Woolley AE, Sharma N, Zhou G, **Kim A**, Ryan E, Joyce M, Goldberg H, Givertz M, Mehra M, Woodcome E, Durney V, Marshall S, Townsend K, Coppolino A, Tullius S, Malek S, Mallidi H, Baden L, Chandraker A. Humoral Response After a Third Dose of SARS-CoV-2 mRNA Vaccine in Transplant Recipients. ATC, June 2022. Oral Presentation.
- 13. **Kim AJ**, Goldberg HJ, Thaniyavarn T, Kennedy JC, Coppolino A, Mallidi HR, Lee SF, Joyce MM, Kovac V, Issa NC, Harris CE, LaCasce AS, Sharma NS, Baden LR, Woolley AE. Epstein-Barr Virus Surveillance in Lung Transplantation: Post-transplant Lymphoproliferative Disorder and Impact on Survival. *Open Forum Infect Dis*. 2022;9(Supplement_2):S150. doi:10.1093/ofid/ofac492.286
- 14. Harris CE, Mehta A, Kim AJ, Goldberg HJ, Mallidi HR, Townsend K, Coppolino A, Thaniyavarn T, Kennedy JC, Lee SF, Durney V, Marshall S, Fenty-Scotland J, Cosimi LA, Kovac V, Issa NC, Baden LR, Sharma NS, Woolley AE. The Impact of Staphylococcus aureus Peri-transplant Cultures on Six-Month Outcomes in Lung Transplantation. *Open Forum Infect Dis*. 2022;9(Supplement_2):S856. doi: 10.1093/ofid/ofac492.1744